ClinicalTrials.Veeva

Menu
Sarasota Arthritis Center | Sarasota, FL logo

Sarasota Arthritis Center | Sarasota, FL

Research site

Site insights

Top conditions

Top treatments

Methotrexate
MTX
Ixekizumab
Abatacept
ABT-494
Upadacitinib
Adalimumab
Tocilizumab
Ianalumab
MM-093

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Stacy Yonker

Verified by this site

Active trials

10 of 47 total trials

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous syst...

Enrolling
Diffuse Cutaneous Systemic Sclerosis
Drug: Ianalumab
Drug: Placebo

The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjogrens syndrome who have previously...

Enrolling
Sjogrens Syndrome
Other: Placebo
Drug: Ianalumab (VAY736)

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).The main aim of the s...

Enrolling
Psoriatic Arthritis
Drug: Active Comparator
Drug: Zasocitinib

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Enrolling
Sjögren's Syndrome
Other: Placebo
Drug: Deucravacitinib

The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at leas...

Active, not recruiting
Obesity
Psoriatic Arthritis
Drug: Tirzepatide
Drug: Ixekizumab

The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (S...

Enrolling
Sjogrens Syndrome
Drug: Placebo
Drug: Standard of care treatment

The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia...

Enrolling
Polymyalgia Rheumatica
Biological: Secukinumab

This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with gi...

Active, not recruiting
Giant Cell Arteritis (GCA)
Biological: Secukinumab 150 mg
Other: Placebo

The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) f...

Active, not recruiting
Polymyalgia Rheumatica
Drug: Secukinumab 150 mg
Other: Placebo to secukinumab

A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with activ...

Active, not recruiting
Sjogren Syndrome
Other: Placebo
Biological: VAY736

Trial sponsors

Bristol-Myers Squibb (BMS) logo
Novartis logo
Lilly logo
Pfizer logo
AbbVie logo
CSL Behring logo
Merrimack Pharmaceuticals logo
Purdue Pharma logo
Roche logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems